Anti-Ro and anti-La antibodies define a disease with a higher rate of extraglandular manifestations and more active immunological status, when compared with ‘seronegative’ SS cases (without anti-Ro or anti-La antibodies). This evidence concerns the gene SSB and synovial sarcoma.